The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    October 2020

  • Pages
    182

  • View Count
    1189

Example Insights

Diabetes-Monitoring-Devices-Market-Context 	Diabetes-Monitoring-Devices-Market-List-of-Diabetes-Monitoring-Devices Diabetes-Monitoring-Devices-Market-Diabetes-Monitoring-Device-Developers
Diabetes-Monitoring-Devices-Market-Distribution Diabetes-Monitoring-Devices-Market-Comptetitiveness-Analysis Diabetes-Monitoring-Devices-Market-Partnership-and-Collaborations
Diabetes-Monitoring-Devices-Market-Big-Pharma-Initiatives Diabetes-Monitoring-Devices-Market-Market-Forcast Diabetes-Monitoring-Devices-Market-Distribution-by-Geography

 

Overview

Diabetes is one of the seven leading causes of death and disability across the world. According to the World Health Organization (WHO), more than 1.6 million deaths are directly attributed to diabetes each year. In 2019, the global expenditure on diabetes treatment and disease management was estimated to be over USD 750 billion; this is indicative of the significant burden on patients and the global healthcare system. Timely glucose monitoring helps prevent unwanted glucose fluctuations (hyperglycemia / hypoglycemia), which are known to have serious implications, including (but not limited to) kidney damage, cardiovascular complications, visual impairment, diabetic ketoacidosis and circulatory defects (some of which are known to progress to a stage requiring amputation). The current gold standard for self-monitoring of blood glucose level involves the use glucose meters. These are compact devices designed to measure glucose levels in blood, which is typically extracted (using a small needle) from patients’ fingertips or forearms. For adequate glycemic control, it is essential for diabetics to measure glucose levels multiple (3-4) times in a day; since the process involves the use of a needle, compliance is a primary concern. Moreover, there are several other concerns, such as inaccurate readings and needlestick injuries, associated with the use of conventional glucose monitoring devices.

Over time, a number of companies have developed advanced variants of the conventional blood glucose monitors that are portable, and minimally- / non-invasive. Many such next generation solutions have connectivity features, which enable patients’ health data to be captured and shared with medical professionals, upon request. In addition, there are a number of innovative continuous glucose monitoring (CGM) systems, which are designed to provide real-time insights on blood glucose levels. Newer variants of these products are now chockful of intuitive software that enables patients to quickly make important treatment-related decisions. This field is presently the epicenter of innovation in the diabetes market; a popular example is the artificial pancreas, which is basically a combination of a CGM system and a large volume wearable injector, powered by intuitive algorithms that drive the delivery of insulin and glucagon. The diabetes monitoring devices market is anticipated to witness steady growth, largely driven by the increasing diabetic patient population and the introduction of advanced and cost effective solutions, in the coming years.

Scope of the Report

The “Diabetes Monitoring Devices Market, 2020-2030” report features an extensive study of the current market landscape and the likely adoption of diabetes monitoring devices, over the next decade. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • An overview of current market landscape of the diabetes monitoring devices, providing information on device specifications, such as type of device (self-monitoring blood glucose device and continuous blood glucose monitoring devices), current status of development (preclinical, clinical and marketed), target patient segment (children, adults and elderly patients), analyte procurement (invasive, non-invasive and minimally invasive), volume of analyte used (less than 0.8 µL, 0.8 to 2 µL and more than 2 µL), processing speed (fast and slow), wearability (wearable and non-wearable), wireless connectivity, water resistance potential, provision for alerts / alarms, device memory attributes and glucose measurement range. In addition, the report presents the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size, location of headquarters and leading developers. 
  • A detailed competitiveness analysis of diabetes monitoring devices, taking into consideration the supplier power (based on the experience / expertise of the developer) and product specifications (type of device, current status of development, target patient segment,  analyte procurement, volume of analyte used, processing speed, wireless connectivity, water resistance potential, provision for alerts / alarms and device memory attributes).
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020 (till August), covering product / technology integration agreements, commercialization agreements, distribution agreements, product development agreements, acquisitions, product development and commercialization agreements and other relevant types of deals.
  • Elaborate profiles of prominent companies that develop diabetes monitoring devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. 
  • A review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 5 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes monitoring devices. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall diabetes monitoring devices market with a detailed market segmentation on the [A] type of device (self-monitoring blood glucose device and continuous blood glucose monitoring device), [B] diabetes type (type 1 diabetes and type 2 diabetes), [C] device component (self-monitoring blood glucose devices: lancing device, blood glucose meter and testing strips; continuous glucose monitoring devices: sensors, transmitter and receiver) and [D] key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

Key Questions Answered

  • Which are the leading diabetes monitoring device developers?
  • What are the popular monitoring devices currently being marketed / developed in this domain? 
  • What novel / advanced features are device developers focusing on to maintain a competitive edge in the market?
  • What kind of partnership models are commonly adopted by stakeholders in this industry? 
  • What initiatives big pharma companies have taken to expand their existing capabilities and comply with industry benchmarks?
  • What are the factors that are likely to influence the evolution of this market?         
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the diabetes monitoring devices market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to diabetes and a discussion on the various existing challenges in diabetes monitoring. Additionally, it features brief descriptions of various diabetes monitoring devices and concludes with a discussion on the future trends that are likely to impact this emerging market segment. 

Chapter 4 includes an assessment of current market landscape of the diabetes monitoring devices, based on various parameters, such as type of device (self-monitoring blood glucose device and continuous blood glucose monitoring devices), current status of development (preclinical, clinical and marketed), target patient segment (children, adults and elderly patients), analyte procurement (invasive, non-invasive and minimally invasive), volume of analyte used (less than 0.8 µL, 0.8 to 2 µL and more than 2 µL), processing speed (fast and slow), wearability (wearable and non-wearable), wireless connectivity, water resistance potential, provision for alerts / alarms, device memory attributes and glucose measurement range. In addition, the report presents the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size, location of headquarters and leading developers. 

Chapter 5 presents a detailed competitiveness analysis of diabetes monitoring devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, current status of development, target patient segment, analyte procurement, volume of analyte used, processing speed, wireless connectivity, water resistance potential, provision for alerts / alarms and device memory attributes). 

Chapter 6 features an analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2015-2020 (till August). It provides a brief description on the various types of partnership models (product / technology integration agreements, commercialization agreements, distribution agreements, product development agreements, acquisitions, product development and commercialization agreements and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, type of device mentioned in the agreement and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. 

Chapter 7 provides detailed profiles of the prominent companies that develop diabetes monitoring devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. 

Chapter 8 provides a review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as diversity of device portfolio number of marketed diabetes and clinical-stage diabetes drugs, diabetes type, type of diabetes drug evaluated and partnerships.

Chapter 9 presents an insightful market forecast analysis, highlighting the future potential of diabetes monitoring devices till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of device (self-monitoring blood glucose device and continuous glucose monitoring device), [B] diabetes type (type 1 diabetes and type 2 diabetes), [C] device component (self-monitoring blood glucose devices: glucose meters, test strips and lancets; continuous glucose monitoring devices: sensors, transmitters and receivers) and [D] key geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and rest of the world).

Chapter 10 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the diabetes monitoring devices market.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Ambuj Jain (General Manager-Business Development, Cambridge Consultants), Ron Erickson (Founder and Chairman, Know Labs)

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Diabetes
3.2.1. Classification of Diabetes
3.2.1.1. Type 1 Diabetes
3.2.1.2. Type 2 Diabetes
3.2.1.3. Gestational Diabetes 

3.3. Key Challenges Associated with Diabetes Monitoring
3.4. Diabetes Monitoring Devices
3.4.1. Devices for Self-Monitoring of Blood Glucose Levels
3.4.1.1. Blood Glucose Meter
3.4.1.2. Testing Strips
3.4.1.3. Lancets

3.4.2. Continuous Blood Glucose Monitoring Devices
3.4.2.1. Sensors
3.4.2.2. Transmitters
3.4.2.3. Receivers
3.4.2.4. Patches

3.5. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Diabetes Monitoring Devices: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Target Patient Segment
4.2.4. Analysis by Analyte Procurement
4.2.5. Analysis by Volume of Analyte Used
4.2.6. Analysis by Processing Speed
4.2.7. Analysis by Wearability
4.2.8. Analysis by Wireless Connectivity
4.2.9. Analysis by Water Resistance Potential
4.2.10. Analysis by Provisions for Alerts / Alarms 
4.2.11. Analysis by Device Memory Attributes 
4.2.12. Analysis by Glucose Measurement Range 

4.3. Diabetes Monitoring Devices: List of Developers
4.3.1. Analysis by Type of Developer
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Company Size
4.3.4. Analysis by Geographical Location
4.3.5. Leading Developers: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Methodology
5.2.1. Product Competitiveness Analysis: Diabetes Monitoring Devices
5.2.1.1. Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices 
5.2.1.2. Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices 

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Diabetes Monitoring Devices: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year and Type of Partnership
6.3.4. Analysis by Type of Device
6.3.5. Most Active Players: Analysis by Number of Partnerships
6.3.6. Geographical Analysis
6.3.6.1. Region-wise Distribution
6.3.6.2. Country-wise Distribution

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. ApexBio
7.2.1. Company Overview
7.2.2. Diabetes Monitoring Devices Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Ascensia Diabetes Care
7.3.1. Company Overview
7.3.2. Diabetes Monitoring Devices Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. i-SENS
7.4.1. Company Overview
7.4.2. Diabetes Monitoring Devices Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Oak Tree Health
7.5.1. Company Overview
7.5.2. Diabetes Monitoring Devices Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. SD Biosensor
7.6.1. Company Overview
7.6.2. Diabetes Monitoring Devices Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. TaiDoc Technology
7.7.1. Company Overview
7.7.2. Diabetes Monitoring Devices Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. VivaCheck Laboratories 
7.8.1. Company Overview
7.8.2. Diabetes Monitoring Devices Portfolio
7.8.3. Recent Developments and Future Outlook

8. DIABETES MONITORING DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives of Big Pharma Players
8.3.1. Analysis by Type of Disease Management Solution
8.3.2. Analysis by Number of Marketed and Clinical-Stage Diabetes Drugs
8.3.3. Analysis by Diabetes Type
8.3.4. Analysis by Type of Drug
8.3.5. Analysis by Number of Partnerships

8.4. Competitive Benchmarking of Big Pharma Players
8.4.1. Spider Web Analysis: Company A
8.4.2. Spider Web Analysis: Company B
8.4.3. Spider Web Analysis: Company C
8.4.4. Spider Web Analysis: Company D
8.4.5. Spider Web Analysis: Company E

9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Assumptions
9.3. Overall Diabetes Monitoring Devices Market, 2020-2030
9.4. Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device
9.5. Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030
9.5.1. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type
9.5.2. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component 
9.5.3. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution
9.5.3.1. Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030
9.5.3.2. Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030
9.5.3.3. Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030
9.5.3.4. Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030
9.5.3.5. Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030
9.5.3.6. Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030

9.6. Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030
9.6.1. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type
9.6.2. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component
9.6.3. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution
9.6.3.1. Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030
9.6.3.2. Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030
9.6.3.3. Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030
9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030
9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030
9.6.3.6. Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030

10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Cambridge Consultants
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Ambuj Jain, General Manager- Business Development

11.3. Know Labs
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Ron Erickson, Founder and Chairman

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 4.1 Diabetes Monitoring Devices: Distribution by Type of Device
Figure 4.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
Figure 4.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
Figure 4.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
Figure 4.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
Figure 4.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
Figure 4.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
Figure 4.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
Figure 4.9 Diabetes Monitoring Devices: Distribution by Processing Speed
Figure 4.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
Figure 4.11 Diabetes Monitoring Devices: Distribution by Wearability
Figure 4.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
Figure 4.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
Figure 4.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
Figure 4.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
Figure 4.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
Figure 4.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
Figure 4.18 Diabetes Monitoring Devices: Distribution by Device Memory Attributes
Figure 4.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
Figure 4.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
Figure 4.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
Figure 4.22 Diabetes Monitoring Device Developers: Distribution by Company Size
Figure 4.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
Figure 4.24 Leading Developers: Analysis by Number of Products
Figure 5.1 Continuous Blood Glucose Monitoring Devices: Dot Plot Analysis
Figure 5.2 Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices
Figure 5.3 Self-Monitoring Blood Glucose Devices: Dot Plot Analysis
Figure 5.4 Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Type of Device
Figure 6.5 Most Active Players: Analysis by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Region-wise Distribution
Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
Figure 8.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Initiatives: Distribution by Type of Disease Management Solution
Figure 8.3 Big Pharma Initiatives: Distribution by Number of Marketed and Clinical-Stage Diabetes Drugs
Figure 8.4 Big Pharma Initiatives: Distribution by Diabetes Type
Figure 8.5 Big Pharma Initiatives: Distribution by Type of Drug
Figure 8.6 Big Pharma Initiatives: Distribution by Number of Partnerships
Figure 8.7 Spider Web Analysis: Company A
Figure 8.8 Spider Web Analysis: Company B
Figure 8.9 Spider Web Analysis: Company C
Figure 8.10 Spider Web Analysis: Company D
Figure 8.11 Spider Web Analysis: Company E
Figure 9.1 Overall Diabetes Monitoring Devices Market, 2020-2030 (USD Billion)
Figure 9.2 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Figure 9.3 Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030 (USD Billion)
Figure 9.4 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Figure 9.5 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Figure 9.6 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Figure 9.7 Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030 (USD Billion)
Figure 9.8 Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030 (USD Billion)
Figure 9.9 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 9.10 Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030 (USD Billion)
Figure 9.11 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 9.12 Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030 (USD Billion)
Figure 9.13 Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030 (USD Billion)
Figure 9.14 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Figure 9.15 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Figure 9.16 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Figure 9.17 Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030 (USD Billion)
Figure 9.18 Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030 (USD Billion)
Figure 9.19 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 9.20 Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030 (USD Billion)
Figure 9.21 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 9.22 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030 (USD Billion)
Figure 10.1 Diabetes Monitoring Device Market: Concluding Remarks

List Of Tables

Table 3.1 Blood Sugar Levels in Diabetic Patients
Table 3.2 Difference between Self-Monitoring and Continuous Monitoring Devices
Table 3.3 Glucose Monitoring Times and Frequency
Table 4.1 List of Diabetes Monitoring Devices
Table 4.2 Diabetes Monitoring Devices: List of Developers
Table 6.1 Diabetes Monitoring Devices: List of Partnerships, 2015-2020 (Till August)
Table 7.1 Leading Diabetes Monitoring Device Developers
Table 7.2 ApexBio: Company Overview
Table 7.3 ApexBio: Diabetes Monitoring Devices
Table 7.4 Ascensia Diabetes Care: Company Overview
Table 7.5 Ascensia Diabetes Care: Diabetes Monitoring Devices
Table 7.6 Ascensia Diabetes Care: Recent Developments and Future Outlook
Table 7.7 i-SENS: Company Overview
Table 7.8 i-SENS: Diabetes Monitoring Devices
Table 7.9 i-SENS: Recent Developments and Future Outlook
Table 7.10 Oak Tree Health: Company Overview
Table 7.11 Oak Tree Health: Diabetes Monitoring Devices
Table 7.12 SD Biosensor: Company Overview
Table 7.13 SD Biosensor: Diabetes Monitoring Devices
Table 7.14 SD Biosensor: Recent Developments and Future Outlook
Table 7.15 TaiDoc Technology: Company Overview
Table 7.16 TaiDoc Technology: Diabetes Monitoring Devices
Table 7.17 VivaChek Laboratories: Company Overview
Table 7.18 VivaChek Laboratories: Diabetes Monitoring Devices
Table 7.19 VivaChek Laboratories: Recent Developments and Future Outlook
Table 8.1 Top Big Pharma Players in Diabetes Domain
Table 8.2 Big Pharma Players: Spider-Web Analysis (Input Data)
Table 11.1 Cambridge Consultants: Company Snapshot
Table 11.2 Know Labs: Company Snapshot
Table 12.1 Diabetes Monitoring Devices: Distribution by Type of Device
Table 12.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
Table 12.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
Table 12.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
Table 12.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
Table 12.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
Table 12.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
Table 12.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
Table 12.9 Diabetes Monitoring Devices: Distribution by Processing Speed
Table 12.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
Table 12.11 Diabetes Monitoring Devices: Distribution by Wearability
Table 12.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
Table 12.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
Table 12.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
Table 12.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
Table 12.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
Table 12.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
Table 12.18 Diabetes Monitoring Devices: Distribution by Distribution by Device Memory Attributes
Table 12.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
Table 12.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
Table 12.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
Table 12.22 Diabetes Monitoring Device Developers: Distribution by Company Size
Table 12.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
Table 12.24 Leading Developers: Analysis by Number of Products
Table 12.25 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.28 Partnerships and Collaborations: Distribution by Type of Device
Table 12.29 Most Active Players: Analysis by Number of Partnerships
Table 12.30 Partnerships and Collaborations: Region-wise Distribution
Table 12.31 Partnerships and Collaborations: Country-wise Distribution
Table 12.32 Overall Diabetes Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.33 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Table 12.34 Overall Self-Monitoring Blood Glucose Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.35 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Table 12.36 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Table 12.37 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Table 12.38 Self-Monitoring Blood Glucose Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.39 Self-Monitoring Blood Glucose Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.40 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.41 Self-Monitoring Blood Glucose Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.42 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.43 Self-Monitoring Blood Glucose Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.44 Overall Continuous Blood Glucose Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.45 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Table 12.46 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Table 12.47 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Table 12.48 Continuous Blood Glucose Monitoring Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.49 Continuous Blood Glucose Monitoring Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.50 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.51 Continuous Blood Glucose Monitoring Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.52 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion
Table 12.53 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)

List Of Company

The following companies and organizations have been mentioned in the report. 

  1. Abbott
  2. ABOX
  3. ACON Laboratories
  4. AgaMatrix
  5. AlDanah Medical
  6. Alertgy
  7. APExBIO
  8. Apple
  9. Arcadia Group
  10. ArKl Medical
  11. ARKRAY
  12. Ascensia Diabetes Care
  13. BeatO
  14. Beurer
  15. Bigfoot Biomedical
  16. Biolinq
  17. Blue Cross and Blue Shield of Minnesota
  18. Bruno Farmaceutici 
  19. BTNX
  20. CEI Technology
  21. Cellnovo Group
  22. Chemglass Life Sciences
  23. CnogaCare
  24. Companion Medical
  25. Control D
  26. CuraTec Nordic
  27. Current Health
  28. Dallas Burston Ethitronix 
  29. DarioHealth
  30. Debiotech 
  31. Dexcom
  32. Diabeto
  33. DiaMonTech 
  34. Diasend
  35. Diathrive
  36. DKSH
  37. Dnurse Technology
  38. Echo Therapeutics
  39. Eli Lilly
  40. EPS Biotechnology 
  41. Essenlife Bioscience
  42. Fitbit
  43. Fleming Medical
  44. ForaCare
  45. Fudakang Industrial
  46. GE Healthcare
  47. Glooko
  48. GlucoRx
  49. Glucosense Diagnostics
  50. Glucovation
  51. Gluco-Z
  52. GluSense
  53. GlySens
  54. GlySure
  55. Glytec
  56. GraphWear Technologies
  57. Guangzhou Guang Yuan Biological Pharmaceutical
  58. Hangzhou Sejoy Electronics & Instruments
  59. Health Alliance Plan
  60. Health2Sync
  61. Hello Heart
  62. Henry Schein Medical
  63. HoyHealth
  64. IBM
  65. Indigo 
  66. Infinovo Medical
  67. Inside Biometrics
  68. Insulet
  69. Integrated Medical Sensors
  70. Integrity Applications
  71. i-SENS
  72. JDRF
  73. Keto-Mojo
  74. Klue
  75. Know Labs
  76. KTH Royal Institute of Technology
  77. LG Life Sciences
  78. LifeCaring Technologies 
  79. LifePlus
  80. LifeScan
  81. Livongo Health
  82. MediReva
  83. MediVena
  84. Medtronic
  85. Medtrum Technologies
  86. META
  87. Metronom Health
  88. Millennium Medical Supplies
  89. Morepen Laboratories
  90. National Diagnostic Products
  91. Nemaura Medical
  92. NovioSense
  93. Novo Nordisk
  94. Nutrino Health (acquired by Medtronic)
  95. Oak Tree Health
  96. OK Biotech
  97. Omada Health
  98. One Drop
  99. Pacific Diabetes Technologies
  100. Palmdoc
  101. PercuSense
  102. Pinnacle Technology
  103. PKvitality
  104. POCTech 
  105. Prediktor Medical
  106. Prodigy Diabetes Care
  107. Qualcomm Life 
  108. Quattro Folia
  109. Roche
  110. Rubin Medical
  111. SanaVita Medical
  112. Sano Intelligence
  113. Sanofi
  114. Sanvita Medical
  115. SD BIOSENSOR
  116. Senseonics
  117. SFC Fluidics
  118. Shezhen Jiacom Technology
  119. Smart Meter
  120. Spirit Health
  121. TaiDoc Technology
  122. Tandem Diabetes Care 
  123. Terumo Medical
  124. Tianjin HUAC Healthcare Technology 
  125. Tidepool
  126. TPMENA
  127. Trividia Health
  128. University of Bath
  129. University of California
  130. Validic
  131. Verily Life Sciences
  132. VivaChek Laboratories
  133. Voluntis
  134. Welldoc
  135. Xuzhou Yongkang Electronic Science Technology
  136. Ypsomed

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com